Aditya Bardia, MD
Enriched profileProfessor of Medicine; Program Director, Breast Medical Oncology; Assistant Chief (Translational Research), Division of Hematology-Oncology; Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center · David Geffen School of Medicine at UCLA
Aditya Bardia is Professor of Medicine; Program Director, Breast Medical Oncology; Assistant Chief (Translational Research), Division of Hematology-Oncology; Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center at David Geffen School of Medicine at UCLA. OpenAlex indexes 1,145 publications with 39,602 citations (h-index 90); ClinicalTrials.gov lists 4 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Aditya Bardia is Professor of Medicine at David Geffen School of Medicine at UCLA / UCLA Health Jonsson Comprehensive Cancer Center. The public record shows 1,145 publications with 39,602 citations (h-index 90), centered on Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Genomics and Diagnostics. It also documents an investigator role on 3 registered clinical trials.
- Most recent indexed publication: 2026 · Nature nanotechnology
- Top research focus: Advanced Breast Cancer Therapies
- 3 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 65 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 319.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Sponsor: Stemline Therapeutics, Inc.
- Fulvestrant + Neratinib In Breast Cancer
Sponsor: Massachusetts General Hospital
Industry payments
26 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202510 payments$17,726openpaymentsdata.cms.gov ↗
- Eli Lilly and CompanyProgram year20254 payments
- Gilead Sciences, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Aromatase Inhibitor61.3%Letrozole80%Exemestane20%Part D<11 patientsKinase inhibitor25.5%Ibrance59%Tagrisso41%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Activating a B cell immune response regresses immunologically cold tumours.
Nature nanotechnology
Article2026 - ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer.
Nature communications
Article2026 - Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.
Clinical cancer research
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study1,802 citations2020
- 04Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer1,551 citations2021
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/aditya-bardia-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/aditya-bardia-a1239b5a
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Aditya-Bardia-42468506
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
videopodcast.researchtopractice.com/breast-cancer-aditya-bardia-md-mph
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →videopodcast.researchtopractice.com ↗ - Other
bcrf.org/researchers/aditya-bardia
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bcrf.org ↗ - Other
breastcancer.org/podcast/enhertu-her2-low-ultralow-breast-cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →breastcancer.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- Internal Medicine Residency
Mayo Clinic College of Medicine and Science, Rochester, MN
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Medical Oncology & Hematology Fellowship
Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- Editorial board member
The Oncologist, Therapeutic Advances in Medical Oncology, and NPJ Precision Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Secondary affiliations
appointments beyond the home institution- Previously Director of Breast Cancer Research
Massachusetts General Hospital Cancer Center (2021-2023), and faculty at Harvard Medical School
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →audiomedica.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Breastcancer.org podcast appearances
e.g. "Enhertu, HER2-Low, and -Ultralow Metastatic Breast Cancer" and "Experimental Elacestrant"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →breastcancer.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Finn, MD
David Geffen School of Medicine at UCLA
Edward Garon, MD
David Geffen School of Medicine at UCLA
Donald Tashkin, MD
David Geffen School of Medicine at UCLA
Gottfried Konecny, MD
David Geffen School of Medicine at UCLA